Your browser doesn't support javascript.
loading
Knowledge of Cannabinoid Content Among People Living with HIV Who Use Cannabis: a Daily Diary Study.
Coelho, Sophie G; Rueda, Sergio; Costiniuk, Cecilia T; Jenabian, Mohammad-Ali; Margolese, Shari; Mandarino, Enrico; Shuper, Paul A; Hendershot, Christian S; Cunningham, John A; Arbess, Gordon; Singer, Joel; Wardell, Jeffrey D.
Afiliação
  • Coelho SG; Department of Psychology, York University, 277 Behavioural Sciences Building, 4700 Keele St., Toronto, ON, Canada.
  • Rueda S; Institute for Mental Health Policy Research and Campbell Family Mental Health Research Institute, Centre for Addiction and Mental Health, Toronto, ON, Canada.
  • Costiniuk CT; Department of Psychiatry, University of Toronto, Toronto, ON, Canada.
  • Jenabian MA; CIHR Canadian HIV Trials Network, Vancouver, BC, Canada.
  • Margolese S; CIHR Canadian HIV Trials Network, Vancouver, BC, Canada.
  • Mandarino E; Chronic Viral Illness Service and Division of Infectious Diseases, Department of Medicine, McGill University Health Centre, Montreal, QC, Canada.
  • Shuper PA; Infection and Immunity in Global Health Program, Research Institute of the McGill University Health Centre, Montreal, QC, Canada.
  • Hendershot CS; CIHR Canadian HIV Trials Network, Vancouver, BC, Canada.
  • Cunningham JA; Department of Biological Sciences, Université du Québec á Montréal, Montreal, QC, Canada.
  • Arbess G; CIHR Canadian HIV Trials Network, Vancouver, BC, Canada.
  • Singer J; CIHR Canadian HIV Trials Network, Vancouver, BC, Canada.
  • Wardell JD; Institute for Mental Health Policy Research and Campbell Family Mental Health Research Institute, Centre for Addiction and Mental Health, Toronto, ON, Canada.
Int J Behav Med ; 2023 Oct 04.
Article em En | MEDLINE | ID: mdl-37794278
BACKGROUND: Many people living with HIV (PLWH) use cannabis for medicinal reasons. Patients' knowledge of the tetrahydrocannabinol (THC) and cannabidiol (CBD) concentrations of the cannabis products they use may be important in helping patients achieve symptom relief while guarding against potential risks of cannabis use. However, no studies have examined cannabinoid concentration knowledge among PLWH. METHOD: PLWH (N = 29; 76% men, mean age 47 years) reporting cannabis use for both medicinal and nonmedicinal reasons completed daily surveys over 14 days assessing cannabis products used, knowledge of cannabinoid concentrations of cannabis products used, cannabis use motives (medicinal, nonmedicinal, both), and positive and negative cannabis-related consequences. Across the 361 cannabis use days captured on the daily surveys, at least some knowledge of cannabinoid concentrations was reported on an average of 43.1% (for THC) and 26.6% (for CBD) of the days. RESULTS: Generalized linear mixed models revealed that participants were more likely to report knowing THC and CBD concentrations on days when they used non-flower forms of cannabis relative to days when they used cannabis flower only. Participants who used cannabis for medicinal reasons on a greater proportion of days had greater knowledge of cannabinoid concentration overall across days. Further, greater overall knowledge of cannabinoid concentrations was associated with fewer reported negative cannabis-related consequences. CONCLUSIONS: Findings suggest that among PLWH, knowledge of cannabinoid concentrations may be higher when using non-flower cannabis products and among those reporting primarily medicinal cannabis use. Moreover, knowledge of cannabinoid concentration may protect against negative cannabis-related consequences in this population.
Palavras-chave

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Tipo de estudo: Prognostic_studies Idioma: En Revista: Int J Behav Med Ano de publicação: 2023 Tipo de documento: Article

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Tipo de estudo: Prognostic_studies Idioma: En Revista: Int J Behav Med Ano de publicação: 2023 Tipo de documento: Article